Last €11.92 EUR
Change Today +0.17 / 1.45%
Volume 2.7K
ADOC On Other Exchanges
Symbol
Exchange
EN Paris
OTC US
Frankfurt
As of 3:51 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

adocia sas (ADOC) Snapshot

Open
€11.66
Previous Close
€11.75
Day High
€11.92
Day Low
€11.66
52 Week High
02/14/14 - €20.00
52 Week Low
09/27/13 - €4.94
Market Cap
74.0M
Average Volume 10 Days
31.5K
EPS TTM
--
Shares Outstanding
6.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADOCIA SAS (ADOC)

Related News

No related news articles were found.

adocia sas (ADOC) Related Businessweek News

No Related Businessweek News Found

adocia sas (ADOC) Details

Adocia Société Anonyme, a biotechnology company, develops medicines from therapeutic proteins. The company focuses on insulin therapy and the treatment of diabetic foot ulcer based on its BioChaperone technological platform. Its product pipeline includes BioChaperone PDGF-BB, which has completed Phase II clinical trials for the treatment of diabetic foot ulcer, as well as in pre clinical stage for the treatment of venous ulcer, and bedsores and burns; BioChaperone insulin that is in Phase II clinical trials, as well as in pre clinical stage for the treatment of diabetes; and BioChaperone for monoclonal antibodies, which is in pre clinical stage. Adocia Société Anonyme was founded in 2005 and is based in Lyon, France.

69.2 Employees
Last Reported Date: 03/25/14
Founded in 2005

adocia sas (ADOC) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

adocia sas (ADOC) Key Developments

Adocia Reports Positive Results from Phase IIa Clinical Study of Ultra-Fast Acting Biochaperone(R) Lispro

Adocia announced positive results from a Phase IIa clinical trial evaluating its innovative ultra-fast formulation of insulin lispro in comparison to Eli Lilly's Humalog(R) commercial insulin. Adocia's formulation incorporates proprietary BioChaperone(R) technology which enables accelerated absorption of prandial insulins. Humalog, which is now off-patent, has annual sales of USD 2.6 billion. The present study met its primary endpoint, showing a significant increase in BioChaperone Lispro bioavailability in the first half-hour compared to Humalog. This parameter is critical as the ultimate goal for prandial insulins is an immediate absorption in the blood following subcutaneous injections. This result demonstrates that BioChaperone Lispro more closely mimics the endogenous insulin secretion observed in healthy individuals in response to a meal.

Adocia Reports Consolidated Earnings Results for the Year Ended December 31, 2013

Adocia reported consolidated earnings results for the year ended December 31, 2013. For the year, the company reported revenue of EUR 5,588,000 against EUR 3,995,000 a year ago. Operating loss was EUR 4,302,000 against EUR 6,070,000 a year ago. Net loss was EUR 4,293,000 against EUR 5,995,000 a year ago. Net cash used in operating activities was EUR 10,796,000 against net cash from operating activities of EUR 919,000 a year ago.

Adocia Société Anonyme Presents at European Smallcap Event, Apr-07-2014

Adocia Société Anonyme Presents at European Smallcap Event, Apr-07-2014 . Venue: Pullman Tour Eiffel, Paris, France.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADOC:FP €11.92 EUR +0.17

ADOC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ADOC.
View Industry Companies
 

Industry Analysis

ADOC

Industry Average

Valuation ADOC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.1x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.9x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADOCIA SAS, please visit www.adocia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.